Doctors need better diagnostics and biomarkers for disease severity to improve clinical outcomes and control epidemics
The diagnostics industry focuses on the “cause” (pathogen) and not on the “effect” (disease severity)
Disease severity matters
• “Research to provide better diagnostics and biomarkers predicting disease severity are urgently needed” – World Health Organization
• Measuring and predicting severity is clinically useful for every disease
FBB Biomed is developing two blood tests
FBB Biomed in the news
• FBB Biomed selected as award-winning business at entrepreneurial venture competition
• GenomeWeb: Iowa startup FBB Biomed pursues RNA blood test to predict disease severity
• How FBB Biomed CEO Dr. Urnovitz translates basic science research into COVID-19 answers
• Interview with Dr. Urnovitz about FBB Biomed’s approach to testing and the battle against COVID-19
Background: the clinical utility of blood RNA
In January 2019 in Martinsried, Germany, FBB Biomed CEO Dr. Urnovitz laid out his vision of using next generation sequencing, bioinformatics and artificial intelligence to understand the genetic language of the blood – RNA.